eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2019
vol. 36
 
Share:
Share:
more
 
 
abstract:
Educational article

New indications for topical ivermectin 1% cream: a case series study

Wioletta Barańska-Rybak, Elżbieta Kowalska-Olędzka

Adv Dermatol Allergol 2019; XXXVI (1): 58-62
Online publish date: 2019/02/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Topical ivermectin is an effective treatment for inflammatory papulopustular rosacea in adults. Positive therapeutic effects of ivermectin due to its potential anti-inflammatory properties could be achieved in the other facial dermatoses.

Aim
To assess the efficacy of topical ivermectin 1% cream therapy in mild and moderate perioral dermatitis (PD), seborrheic dermatitis (SD) and acne vulgaris (AV).

Material and methods
The study comprising 20 patients diagnosed with PD (8), SD (8) and AV (4) was conducted between November 2016 and July 2017. Two scales were applied to establish efficacy of the treatment: Investigator Global Assessment score (IGA) and Patient Global Assessment of Treatment (PGA).

Results
All patients responded to the treatment with topical ivermectin very well with a gradual reduction in inflammatory skin lesions. Complete or almost complete clearance (IGA score 0–1) was achieved in 20 cases. Four patients with PD achieved IGA 0–1 after 4 weeks of treatment, 1 patient after 5 weeks, 2 patients after 6 weeks and 1 patient after 12 weeks. In the total group of 8 patients with SD, 4 presented IGA 0 after 4 weeks of therapy, while 4 patients demonstrated IGA 1 after 6 weeks. Patients with AV required 8 and 10 weeks to obtain IGA 1. Nineteen patients of the studied group reported “very good” or “excellent” response to the therapy, only one patient with AV assessed therapy with topical ivermectin as “good”. The adverse events were transient and manifested as mild-moderate desquamation, stinging and burning in 2 patients with PD.

Conclusions
Topical ivermectin was well tolerated and beneficial for treatment of mild and moderate PD, SD and AV.

keywords:

ivermectin, topical, perioral dermatitis, seborrheic dermatitis, acne vulgaris

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe